使用爱尔兰爵士制药去纤苷需要注意什么事项？

(Defibrotide) was approved by the US FDA on March 30, 2016 for the treatment of severe hepatic veno-occlusive disease in adults and children after hematopoietic stem cell transplantation (usually complicated by renal and pulmonary function abnormalities). This is the first drug approved by the FDA for the treatment of severe hepatic veno-occlusive disease. What should patients pay attention to when using Irish Jazz Pharmaceuticals Defibrotide?

1. Common adverse reactions related to defibrotide sodium (defibrinoside) include bleeding, hypotension, gastrointestinal discomfort (such as nausea, vomiting, abdominal discomfort), and occasional injection site adverse reactions, but most are mild to moderate. Adverse reactions of grade III or above are occasionally seen, such as sepsis, pulmonary edema, cytomegalovirus infection, hypotension, respiratory failure and alveolar hemorrhage. The causal relationship between defibrinated sodium and these adverse reactions cannot be determined.

2. The incidence of adverse reactions of defibrotide sodium (defibrinoside) is highest when used to treat patients with hepatic veno-occlusive disease and lowest when used for prophylaxis, indicating that early application of defibrotide sodium can reduce the incidence of adverse reactions. The condition of patients with hepatic veno-occlusive disease is often more severe and often complicated by MOF, GVHD, infection, etc. It is difficult to determine the clear cause-and-effect relationship between defibrotide and the occurrence of adverse reactions in patients when conducting safety analysis of defibrotide sodium. Compared with historical controls, there was no statistically significant difference in the incidence of adverse reactions in patients, indicating that adverse reactions when using defibrinated sodium may be related to the patient's disease itself.

In January 2019, Jazz Pharmaceuticals and Codiak reached a cooperation in the research and development of new drugs for hematological malignancies and solid tumors with exosome drug delivery as the core. Jazz Pharmaceuticals agreed to pay Codiak $56 million in research funding and up to $20 million in preclinical development milestone payments for five new drug projects in the collaboration. After the completion of Phase I/II clinical trials, Jazz Pharmaceuticals will be responsible for subsequent clinical trials, new drug applications and commercial promotion. As one of the products of Irish Jazz Pharmaceuticals, its efficacy is quite good.

Recommended hot articles: /newsDetail/87093.html